使用68Ga-PSMA-11 PET半自动量化肿瘤体积作为晚期前列腺癌患者生存的生物标志物
本研究提出并评估了一种可半自动量化PSMA PET全身肿瘤体积等生物标志物的软件,在40例接受177Lu-PSMA-617治疗的晚期前列腺癌患者的治疗前PSMA PET/CT上进行验证。半自动与手动读值高度相关,观察者间一致性高,PSMATV50是全因生存的显著预测因子。
要点
- 半自动软件量化PSMATV50与手动读值高度相关(R²=1.000,P<0.001),观察者间一致性高。
- PSMATV50(ml)是全因生存的显著预测因子(HR 1.004,95%CI 1.001-1.006,P=0.002)。
- 多变量回归中PSMATV50仍为显著预测因子(HR 1.004,95%CI 1.001-1.006,P=0.004)。
核心结论
- PSMATV50是一种有前景的PSMA PET生物标志物,所提出的半自动软件可重复且简便地量化该指标。
- PSMATV50是接受177Lu-PSMA-617治疗的晚期前列腺癌患者全因生存的显著预测因子。
研究设计与样本
- 研究提出并评估一种用于半自动量化PSMA PET全身肿瘤体积等生物标志物的软件,实现为研究原型。
- PSMA摄取灶通过局部SUVmax 50%的百分比阈值自动分割,神经网络在PET/CT采集上训练用于器官分割(训练CT 8,632例,验证CT 53例)。
- 分析纳入40例连续接受177Lu-PSMA-617治疗患者的治疗前PSMA PET/CT。
- 在亚队列中由1名核医学医师将半自动结果与手动读值比较,并由2名核医学医师对半自动方法进行观察者间评估。
主要发现
- 手动与半自动PSMA指标高度相关:PSMATV50 R²=1.000,P<0.001;SUVmax R²=0.988,P<0.001。
- 半自动工作流程观察者间一致性高:PSMATV50 R²=1.000,P<0.001,组内相关系数=1.000;SUVmax R²=0.988,P<0.001,组内相关系数=0.997。
- PSMATV50(ml)是全因生存的显著预测因子(HR 1.004,95%CI 1.001-1.006,P=0.002)。
- 在纳入其他生物标志物的多变量回归中PSMATV50仍为显著预测因子(HR 1.004,95%CI 1.001-1.006,P=0.004)。
关键数值与推荐
- PSMA摄取灶自动分割采用局部SUVmax 50%的百分比阈值。
- 神经网络训练使用训练CT 8,632例、验证CT 53例。
- PSMATV50预测全因生存的HR为1.004(95%CI 1.001-1.006,P=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeting PET imaging is becoming the reference standard for prostate cancer staging, especially in advanced disease. Yet, the implications of PSMA PET-derived whole-body tumor volume for overall survival are poorly elucidated to date. This might be because semiautomated quantification of whole-body tumor volume as a PSMA PET biomarker is an unmet clinical challenge. Therefore, in the present study we propose and evaluate a software that enables the semiautomated quantification of PSMA PET biomarkers such as whole-body tumor volume. Methods: The proposed quantification is implemented as a research prototype. PSMA-accumulating foci were automatically segmented by a percental threshold (50% of local SUVmax). Neural networks were trained to segment organs in PET/CT acquisitions (training CTs: 8,632, validation CTs: 53). Thereby, PSMA foci within organs of physiologic PSMA uptake were semiautomatically excluded from the analysis. Pretherapeutic PSMA PET/CTs of 40 consecutive patients treated with 177Lu-PSMA-617 were evaluated in this analysis. The whole-body tumor volume (PSMATV50), SUVmax, SUVmean, and other whole-body imaging biomarkers were calculated for each patient. Semiautomatically derived results were compared with manual readings in a subcohort (by 1 nuclear medicine physician). Additionally, an interobserver evaluation of the semiautomated approach was performed in a subcohort (by 2 nuclear medicine physicians). Results: Manually and semiautomatically derived PSMA metrics were highly correlated (PSMATV50: R2 = 1.000, P < 0.001; SUVmax: R2 = 0.988, P < 0.001). The interobserver agreement of the semiautomated workflow was also high (PSMATV50: R2 = 1.000, P < 0.001, interclass correlation coefficient = 1.000; SUVmax: R2 = 0.988, P < 0.001, interclass correlation coefficient = 0.997). PSMATV50 (ml) was a significant predictor of overall survival (hazard ratio: 1.004; 95% confidence interval: 1.001-1.006, P = 0.002) and remained so in a multivariate regression including other biomarkers (hazard ratio: 1.004; 95% confidence interval: 1.001-1.006 P = 0.004). Conclusion: PSMATV50 is a promising PSMA PET biomarker that is reproducible and easily quantified by the proposed semiautomated software. Moreover, PSMATV50 is a significant predictor of overall survival in patients with advanced prostate cancer who receive 177Lu-PSMA-617 therapy.
引用
- Seifert R, Herrmann K, Kleesiek J, et al. Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer. J Nucl Med. 2020. PMID: 32332147. doi:10.2967/jnumed.120.242057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。